HOOKIPA Pharma Inc. (HOOK) Dividend History

Company News

• Squamous Cell Carcinoma Clinical Trial Pipeline Insights: 75+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | DelveInsight

  The squamous cell carcinoma (SCC) market is experiencing robust growth due to the increasing incidence of the disease and advancements in treatment options. Over 75 companies are working on 80+ pipeline therapies to improve the SCC treatment landscape.

  GlobeNewswire Inc.

  Featured Companies: EXEL MRNA
• Deep Dive Into HOOKIPA Pharma Stock: Analyst Perspectives (4 Ratings)

  HOOKIPA Pharma (NASDAQ:HOOK) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $5.38, along with a high estimate of $6.50 and a low estimate of $5.00. A decline of 17.23% from the prior average price target is evident in the current average. Decoding Analyst Ratings: A Detailed Look In examining recent analyst actions, we gain insights into how financial experts perceive HOOKIPA Pharma. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Brian Abrahams RBC Capital Maintains Outperform $5.00 - Arthur He HC Wainwright & Co. Lowers Buy $5.00 $6.50 Brian Abrahams RBC Capital Maintains Outperform $5.00 - Arthur He HC Wainwright & Co. Maintains Buy $6.50 - Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their ...Full story available on Benzinga.com

  Benzinga
• HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates

  HOOKIPA Pharma (HOOK) delivered earnings and revenue surprises of 45% and 105.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: EQ
• Best Penny Stocks To Buy This Week? 4 To Watch Now

  Looking for penny stocks to buy? Start with a watch list & here are some of the most active stocks to watch today. The post Best Penny Stocks To Buy This Week? 4 To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: FBIO KRON NVDA